Telix Q3 2024 Business Update – Quarterly Revenue Exceeds AU$200M
Telix today provides an update on its revenue and operational performance for the quarter ended 30 September 2024 (Q3...
Read moreLatest News
Category: News
Telix Featured in 13 Abstracts at the Annual Congress of the European Association of Nuclear Medicine (EANM)
Telix today announces thirteen abstract presentations featuring the Company’s ongoing theranostic development, medical technologies (MedTech), and research and innovation (R&I) programs at the 37th Annual Congress of the European Association...
Read more
Australian TGA Approves Additional Indication for Telix’s Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
News,
Telix today announces that the Australian Therapeutic Goods Administration (TGA) has approved the use of Illuccix® (kit for the preparation of 68Ga-PSMA-11[1] injection) to select patients for PSMA[2]-targeted radionuclide...
Read more
Health Canada Approves Label Expansion for Telix’s Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
News,
Telix today announces that Health Canada has approved the use of Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) in selecting patients for PSMA[1]-targeted radionuclide...
Read more
First Patient Dosed in Phase II ‘CA-NINE’ Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
Telix today announces that the first patient has been dosed in a Phase II trial exploring the clinical utility of Telix’s first-in-class investigational PET[1] agent, TLX250-CDx (89Zr-girentuximab) in recurrent clear...
Read more
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
Telix and RLS (USA) Inc., America’s only Joint Commission-accredited radiopharmacy network distributing PET, SPECT and therapeutic radiopharmaceuticals, today announced an agreement by the Company to acquire RLS from its parent...
Read more
Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®
News,
Telix today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as a commercial radiopharmaceutical distributor to supply finished unit doses of its PET agent, Zircaix® (TLX250-CDx)...
Read more
‘Highly Accurate’: Telix’s Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
Telix today announces that primary results from its Phase III ZIRCON trial have been published in The Lancet Oncology, reporting that Telix’s first-in-class investigational PET agent, TLX250-CDx (Zircaix®, 89Zr-girentuximab), is...
Read more
IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
Telix today announces that the Company’s IPAX-1 Phase I study has been published in Neuro-Oncology Advances, confirming the safety and tolerability profile, and early efficacy of TLX101 therapy, in combination...
Read more
Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
Telix today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-CDx, (Pixclara®[1], 18F-floretyrosine or 18F-FET), an investigational PET[2]...
Read more